Isoliquiritigenin reduces experimental autoimmune prostatitis by facilitating Nrf2 activation and suppressing the NLRP3 inflammasome pathway
Molecular Immunology · 2024-05 · 169 · 37-49
DOI: 10.1016/j.molimm.2024.03.002 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Immunology, 2024-05. Verfasst von Rui Feng und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, the First Affiliated Hospital of Anhui Medical University, Anhui Medical University, Hefei, Anhui, PR China; Institute of Urol…. Hauptthemen laut MEDLINE: Chalcones, Prostatitis. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 49 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
BACKGROUND: Chronic prostatitis and chronic pelvic pain syndrome (CP/CPPS) lead to severe irritation and impaired sperm quality in males. However, current therapeutic options often fail to achieve satisfactory effects. Consequently, the investigation of novel treatment strategies or remedies holds substantial clinical importance. As a flavonoid monomer, isoliquiritigenin (ISL) has been shown to possess anti-inflammatory activity, especially in several chronic nonspecific-inflammatory conditions. Thus, an exploration of the possible anti-inflammatory effects of ISL on CP/CPPS, a chronic aseptic inflammation of the prostate, has significant potential. METHODS: An experimental autoimmune prostatitis (EAP) model was used for the evaluation of the anti-inflammatory effects of ISL. It was found that ISL treatment could reduce the secretion and invasion of pro-inflammatory cytokines in prostate tissue. In EAP mice, ISL treatment also reduced oxidative stress (OS) and activation of the NLRP3 inflammasome. In vitro, ISL upregulated the expression of nuclear factor erythroid 2-related factor 2 (Nrf2) and inhibited NLRP3 inflammasome activation in RAW264.7 macrophages exposed to lipopolysaccharide (LPS). RESULTS: Treatment with ISL treatment relieved prostate inflammation and pelvic pain in EAP mice. Both in vivo and in vitro, ISL treatment activated Nrf2/HO-1 signaling, which in turn inhibited oxidative stress and activation of the NLRP3 inflammasome. Blockade of Nrf2/HO-1 signaling abolished the inhibitory effects of ISL on oxidative stress and NLRP3 inflammasome activation. CONCLUSIONS: Isoliquiritigenin reduced experimental autoimmune prostatitis by facilitating Nrf2 activation and suppressing the NLRP3 inflammasome pathway.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, the First Affiliated Hospital of Anhui Medical University, Anhui Medical University, Hefei, Anhui, PR China; Institute of Urology, Anhui Medical University, Hefei, Anhui, PR China; Anhui Province…
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Feng, R., Meng, T., Zhao, X., Yu, W., Li, H., Wang, Z., Chen, J., & Yang, C. (2024). Isoliquiritigenin reduces experimental autoimmune prostatitis by facilitating Nrf2 activation and suppressing the NLRP3 inflammasome pathway. Molecular Immunology, 169, 37-49. https://doi.org/10.1016/j.molimm.2024.03.002
Vancouver
Feng R, Meng T, Zhao X, Yu W, Li H, Wang Z, et al. Isoliquiritigenin reduces experimental autoimmune prostatitis by facilitating Nrf2 activation and suppressing the NLRP3 inflammasome pathway. Molecular Immunology. 2024;169:37-49. doi:10.1016/j.molimm.2024.03.002
BibTeX
@article{Feng2024,
author = {Feng, Rui and Meng, Tong and Zhao, Xiaohu and Yu, Weidong and Li, Haolin and Wang, Zicheng and Chen, Jing and Yang, Cheng},
title = {Isoliquiritigenin reduces experimental autoimmune prostatitis by facilitating Nrf2 activation and suppressing the NLRP3 inflammasome pathway},
journal = {Molecular Immunology},
year = {2024},
volume = {169},
pages = {37--49},
doi = {10.1016/j.molimm.2024.03.002}
}
EUVIMED